Latest & greatest articles for glimepiride

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on glimepiride or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on glimepiride and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for glimepiride

21. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. (PubMed)

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder.In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 (...) diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks. The primary outcome was change in proportion of glycosylated haemoglobin (HbA(1c)). Analysis was done by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NTC00294723.At 52 weeks, HbA(1c) decreased by 0.51% (SD 1.20%) with glimepiride, compared with 0.84% (1.23%) with liraglutide 1.2 mg (difference -0.33%; 95% CI -0.53 to -0.13, p=0.0014

2009 Lancet Controlled trial quality: predicted high

22. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus

A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the long-term clinical and economic impact of liraglutide versus glimepiride as monotherapies in patients with type 2 diabetes mellitus. The authors concluded that liraglutide

2009 NHS Economic Evaluation Database.

23. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. (PubMed)

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers.To compare the effects of an insulin sensitizer, pioglitazone, with an insulin (...) secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes.Double-blind, randomized, multicenter trial at 97 academic and community hospitals in North and South America (enrollment August 2003-March 2006) in 543 patients with coronary disease and type 2 diabetes.A total of 543 patients underwent coronary intravascular ultrasonography and were randomized to receive glimepiride, 1 to 4 mg, or pioglitazone, 15 to 45 mg, for 18 months with titration to maximum

Full Text available with Trip Pro

2008 JAMA Controlled trial quality: predicted high

24. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

25. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. (PubMed)

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. Carotid artery intima-media thickness (CIMT) is a marker of coronary atherosclerosis and independently predicts cardiovascular events, which are increased in type 2 diabetes mellitus (DM). While studies of relatively short duration have suggested that thiazolidinediones such as pioglitazone might reduce progression of CIMT in persons with diabetes, the results of longer (...) studies have been less clear.To evaluate the effect of pioglitazone vs glimepiride on changes in CIMT of the common carotid artery in patients with type 2 DM.Randomized, double-blind, comparator-controlled, multicenter trial in patients with type 2 DM conducted at 28 clinical sites in the multiracial/ethnic Chicago metropolitan area between October 2003 and May 2006. The treatment period was 72 weeks (1-week follow-up). CIMT images were captured by a single ultrasonographer at 1 center and read

Full Text available with Trip Pro

2006 JAMA Controlled trial quality: predicted high

26. Duetact (pioglitazone HCl + glimepiride)

Duetact (pioglitazone HCl + glimepiride) Drug Approval Package: Duetact (pioglitazone HCl + glimepiride) NDA #021925 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Duetact (pioglitazone HCl + glimepiride) Company: Takeda Global Research & Development Center, Inc. Application No.: 021925 Approval Date: 07/28/2006 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: September 4, 2008 Note: Documents in PDF format require the . - - Links on this page

2006 FDA - Drug Approval Package

27. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus Campbell R K Authors' objectives To assess the efficacy and safety of glimepiride with and without insulin in the treatment of type 2 diabetes mellitus. Searching A MEDLINE database search (January 1985 to April 1997) was performed for English (...) language studies, including reviews and abstracts. The author also contacted a manufacturer of glimepiride (Hoechst Marion Roussel) for unpublished study data. Study selection Study designs of evaluations included in the review Large (but actual size unspecified) double-blind, randomised controlled trials (RCTs) were included in the review. Included trials had to be published as an individual study, as part of a review, or pending publication. Relatively small, nonrandomised, noncomparative, open-label

1998 DARE.